Hamamoto Shuzo, Tasaki Yoshihiko, Yamashita Shimpei, Furukawa Junya, Fujita Kazutoshi, Tomida Ryotaro, Miyake Makito, Ito Noriyuki, Iwamoto Hideto, Sugiyama Yosuke, Taguchi Kazumi, Yasui Takahiro
Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Front Oncol. 2024 Sep 2;14:1400041. doi: 10.3389/fonc.2024.1400041. eCollection 2024.
Pretreatment hemoglobin and neutrophil levels were previously reported to be important indicators for predicting the effectiveness of ipilimumab plus nivolumab (IPI + NIVO) therapy for renal cell carcinoma (RCC). Therefore, we aimed to validate this in a large external cohort.
In total, 172 patients with RCC who underwent IPI + NIVO treatment at a multicenter setting were divided into three groups according to their pretreatment hemoglobin and neutrophil levels (group 1: non-anemia; group 2: anemia and low-neutrophil; and group 3: anemia and high-neutrophil).
Group 1 showed better survival than groups 2 and 3 (overall survival: 52.3 vs. 21.4 vs. 9.4 months, respectively; progression-free survival: 12.1 vs. 7.0 vs. 3.4 months, respectively).
In this large cohort, we validated our earlier observation that hemoglobin and neutrophil levels can be reliable predictors of the effectiveness of IPI + NIVO in advanced RCC. Thus, our approach may aid in selecting the optimal first-line therapy for RCC.
先前有报道称，治疗前血红蛋白和中性粒细胞水平是预测伊匹单抗联合纳武单抗（IPI + NIVO）治疗肾细胞癌（RCC）疗效的重要指标。因此，我们旨在在一个大型外部队列中对此进行验证。
共有172例在多中心接受IPI + NIVO治疗的RCC患者，根据其治疗前血红蛋白和中性粒细胞水平分为三组（第1组：非贫血；第2组：贫血且中性粒细胞水平低；第3组：贫血且中性粒细胞水平高）。
第1组的生存期优于第2组和第3组（总生存期：分别为52.3个月、21.4个月和9.4个月；无进展生存期：分别为12.1个月、7.0个月和3.4个月）。
在这个大型队列中，我们验证了我们之前的观察结果，即血红蛋白和中性粒细胞水平可以作为IPI + NIVO治疗晚期RCC疗效的可靠预测指标。因此，我们的方法可能有助于为RCC选择最佳的一线治疗方案。
